BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17706166)

  • 1. Rituximab maintenance in indolent lymphoma: indications and controversies.
    van Oers MH
    Curr Oncol Rep; 2007 Sep; 9(5):378-83. PubMed ID: 17706166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab maintenance therapy: a step forward in follicular lymphoma.
    van Oers MH
    Haematologica; 2007 Jun; 92(6):826-33. PubMed ID: 17550856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab maintenance therapy in indolent NHL: a clinical review.
    Buske C; Hiddemann W
    Leuk Res; 2006 Mar; 30 Suppl 1():S11-5. PubMed ID: 16750673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of rituximab in patients with follicular lymphoma.
    Marcus R
    Clin Oncol (R Coll Radiol); 2007 Feb; 19(1):38-49. PubMed ID: 17305253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
    Vidal L; Gafter-Gvili A; Leibovici L; Dreyling M; Ghielmini M; Hsu Schmitz SF; Cohen A; Shpilberg O
    J Natl Cancer Inst; 2009 Feb; 101(4):248-55. PubMed ID: 19211444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Litchy S; Shaffer DW; Lackey VL; Grimaldi M; Greco FA
    J Clin Oncol; 2005 Feb; 23(6):1088-95. PubMed ID: 15657401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
    Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the role of maintenance rituximab in follicular NHL?
    Maloney DG
    Oncology (Williston Park); 2008 Jan; 22(1):20-6; discussion 26, 29, 33-4. PubMed ID: 18251281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged remission in a patient with relapsed follicular lymphoma after a single course of rituximab.
    Jensen M; Elter T; Engert A; Reiser M
    Onkologie; 2006 Mar; 29(3):90-2. PubMed ID: 16514269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab as maintenance therapy for patients with follicular lymphoma.
    Vidal L; Gafter-Gvili A; Leibovici L; Shpilberg O
    Cochrane Database Syst Rev; 2009 Apr; (2):CD006552. PubMed ID: 19370640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonging remission with rituximab maintenance therapy.
    Hainsworth JD
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):17-21. PubMed ID: 15042530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab maintenance versus retreatment in follicular lymphoma.
    Palla AR; Hamadani M
    Hematol Oncol; 2013 Dec; 31(4):171-8. PubMed ID: 23044794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
    Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
    Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient benefits of maintenance immunotherapy.
    Ghielmini M
    Leuk Res; 2006 Mar; 30 Suppl 1():S22-6. PubMed ID: 16750675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of rituximab maintenance therapy in follicular lymphomas.
    Solal-CĂ©ligny P
    Leuk Res; 2006 Mar; 30 Suppl 1():S16-21. PubMed ID: 16750674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.
    Vidal L; Gafter-Gvili A; Salles G; Dreyling MH; Ghielmini M; Hsu Schmitz SF; Pettengell R; Witzens-Harig M; Shpilberg O
    J Natl Cancer Inst; 2011 Dec; 103(23):1799-806. PubMed ID: 22021664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should all patients with indolent lymphoma be treated with rituximab maintenance therapy? An overview of the data.
    Andemariam B; Leonard JP
    Clin Lymphoma Myeloma; 2006 Oct; 7 Suppl 1():S20-3. PubMed ID: 17101069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatment approaches to indolent non-Hodgkin's lymphoma.
    Seymour JF
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):27-32. PubMed ID: 15042532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab maintenance therapy in follicular lymphoma.
    Forstpointner R; Dreyling M
    Curr Hematol Malig Rep; 2007 Oct; 2(4):213-8. PubMed ID: 20425372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of postremission therapy in follicular lymphoma: efficacy of rituximab maintenance.
    Roy R; Gordon LI
    J Natl Compr Canc Netw; 2011 May; 9(5):563-71. PubMed ID: 21550969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.